abemaciclib
abemaciclib: 74 clinical trials tracked.
abemaciclib evidence translation
What we can confirm
74 tracked trials
What it means
What to watch
Prepared research question
What is verified about abemaciclib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 7 study sponsors
Related indications
Clinical Trial Registry Records (74)showing 10 most recent
A Phase II Trial of Imlunestrant/Abemaciclib/Selinexor in Low Grade Serous Ovarian Cancer and in Endometrioid Endometrial Cancer
Primary endpoint: Objective Response Rate (ORR)
A Phase 1, Open-Label, Randomized, Crossover Study to Investigate the Relative Bioavailability of Abemaciclib (LY2835219) Test and Reference Formulations and an Alternate Administration Method, in Healthy Participants.
Primary endpoint: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
Primary endpoint: Progression-Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Phase I/II Study to Evaluate the Feasibility and Efficacy of Sequential Abemaciclib and Gemcitabine Treatment in Patients With Retinoblastoma (Rb)+ Sarcomas
Primary endpoint: Time course of blood thymidine kinase activity (TKa) (Phase 1 Part A)
A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)
Primary endpoint: (Part 1): Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR)
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART): Adaptive Clinical Treatment (ACT)
Primary endpoint: Proportion of Participants Who Receive an ACT Therapy Based on a SMMART-ACT Tumor Board Recommendation.
A Phase 1 Study of 5-Fluorouracil in Combination With Abemaciclib in Metastatic, Refractory CRC
Primary endpoint: Dose-limiting toxicity (DLT)
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Primary endpoint: Phase 1 Maximum Tolerated Dose
A Phase 2 Multicenter, Double-blind, Randomized-controlled Study of Abemaciclib (CDK4 and 6 Inhibitor) in Newly Diagnosed RB-proficient Grade 3 Meningioma Participants
Primary endpoint: Progression-Free Survival Characteristics Over 24 Months
A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for High-Risk Adipocytic Retroperitoneal Sarcomas
Primary endpoint: Recommended phase 2 dose of abemaciclib in combination with radiation